Observational studyCNS drugs2026
Assessing Cognitive Function over Time in Patients with Refractory Chronic Migraine Who Received Ketamine Infusions: A Prospective, Observational Study.
Observational study in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKetamine infusions are used in the inpatient setting for refractory chronic migraine but are associated with neurotoxicity in rodents at high doses and memory deficits in illicit users. The relationship between ketamine infusions and cognitive function in refractory chronic migraine patients after infusions is unknown. We aimed to determine if patients receiving ketamine infusions for refractory chronic migraine experience changes in cognitive function as assessed by the telephone Montreal Cognitive Assessment.
methodsAdults 18 years or older who were diagnosed with refractory chronic migraine and met criteria for hospitalization with an elective ketamine infusion were recruited for this prospective observational study. All patients had Migraine Disability Assessment grade IV (severe disability) and had previously failed an inpatient treatment with at least one other intravenous infusion. Baseline assessments included current and average pain levels, monthly migraine days, depression history, medications, and initial assessments of the telephone Montreal Cognitive Assessment, Migraine Disability Assessment, and Headache Impact Test-6. Patients were admitted to a dedicated headache unit within 1 month of baseline assessments to undergo a 5-day continuous ketamine infusion to a maximum rate of 1 mg/kg/h. The aforementioned assessments were then repeated at 1, 6, and 12 months. The primary outcome was the change over time in the telephone Montreal Cognitive Assessment, which was analyzed using generalized estimating equations adjusted for age and sex.
resultsA total of 23 patients were analyzed. The mean age was 44.8
conclusionThe study suggests that measurable cognitive impairment did not occur over the course of the 1-year study period in most patients with refractory chronic migraine after receiving a ketamine infusion. However, a few patients experienced worsening telephone Montreal Cognitive Assessment scores, and furthermore, the small sample size and lack of a control group prevent any definitive conclusions. Larger follow-up studies would further establish the safety of ketamine treatment in headache or pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.